MYGN vs PNR · rev $824.5M vs P/E 18, rev $4.18B
Myriad Genetics Inc (MYGN) versus Pentair PLC (PNR) — a side-by-side from cached financials, not a winner call.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Pentair PLC (PNR) is a specialty industrial machinery company listed on NYSE.
Latest reported MYGN revenue for 2025-12-31 was $824.5M. Net income was -$365.9M. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. MYGN currently screens at market cap $413.7M.
Latest reported PNR revenue for 2025-12-31 was $4.18B. Net income was $653.8M. Revenue was up 2.3% from 2024-12-31 to 2025-12-31. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
MYGN currently screens at market cap $413.7M. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
Not investment advice. Open the MYGN and PNR stock pages for the full models.
Not investment advice.